Christine J. Saoud

Array ( [id] => 16570644 [patent_doc_number] => 20210009650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/089698 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16089698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11728044 [patent_doc_number] => 20170189486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/460917 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 81 [patent_no_of_words] => 89672 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15460917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11850282 [patent_doc_number] => 20170224774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'METHOD FOR USING SUPPLEMENTAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) OR ANALOG TO PREVENT OXYGEN INDUCED ARREST OF VESSEL GROWTH AND DISEASE SEQUELA OF PREMATURE INFANT BIRTH' [patent_app_type] => utility [patent_app_number] => 15/425872 [patent_app_country] => US [patent_app_date] => 2017-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1914 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15425872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11850283 [patent_doc_number] => 20170224775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Lv PEPTIDE, ANTI-Lv ANTIBODY AND METHODS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/424816 [patent_app_country] => US [patent_app_date] => 2017-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8288 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15424816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618400 [patent_doc_number] => 20170128587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NANOPARTICLE COMPLEXES OF ANTI-CD20 ANTIBODIES, ALBUMIN AND PACLITAXEL' [patent_app_type] => utility [patent_app_number] => 15/414526 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20273 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618221 [patent_doc_number] => 20170128408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, ALEMTUZUMAB, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/414536 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20275 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15099701 [patent_doc_number] => 10471145 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Methods for treating cancer using nanoparticle complexes of paclitaxel, rituximab, and albumin [patent_app_type] => utility [patent_app_number] => 15/414533 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 92 [patent_no_of_words] => 19244 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618398 [patent_doc_number] => 20170128585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'CANCER TREATMENTS' [patent_app_type] => utility [patent_app_number] => 15/412581 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20274 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11742761 [patent_doc_number] => 20170196833 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, BEVACIZUMAB, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/413257 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20688 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15413257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11742758 [patent_doc_number] => 20170196831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, ANTI-HER2 ANTIBODY, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/412536 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20692 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618395 [patent_doc_number] => 20170128583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NANOPARTICLE COMPLEXES OF PACLITAXEL, TRASTUZUMAB, AND ALBUMIN' [patent_app_type] => utility [patent_app_number] => 15/412554 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20277 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15191359 [patent_doc_number] => 10493150 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => Nanoparticle complexes of paclitaxel, alemtuzumab, and albumin [patent_app_type] => utility [patent_app_number] => 15/412610 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 92 [patent_no_of_words] => 19241 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618397 [patent_doc_number] => 20170128584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'CANCER TREATMENTS' [patent_app_type] => utility [patent_app_number] => 15/412564 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20275 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618399 [patent_doc_number] => 20170128586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'CANCER TREATMENTS' [patent_app_type] => utility [patent_app_number] => 15/412596 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 20276 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15412596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963581 [patent_doc_number] => 20170267735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/411112 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 27774 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13795837 [patent_doc_number] => 20190011457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => BIOMARKERS FOR DIAGNOSING KELOID SKIN OR KELOID SCAR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/070121 [patent_app_country] => US [patent_app_date] => 2017-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 594 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16070121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11714920 [patent_doc_number] => 20170183412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'Human Antigen Binding Proteins That Bind To a Complex Comprising beta-Klotho and an FGF Receptor' [patent_app_type] => utility [patent_app_number] => 15/400800 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 87359 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15400800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963157 [patent_doc_number] => 20200165330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => HIGH-AFFINITY ANTI-VEGF ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/067931 [patent_app_country] => US [patent_app_date] => 2017-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16067931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837397 [patent_doc_number] => 20190022183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => A NOVEL LIQUID FORMULATION OF LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/066877 [patent_app_country] => US [patent_app_date] => 2016-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11589702 [patent_doc_number] => 20170114113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'POLYPEPTIDES AS APELIN INHIBITORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/391893 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 6627 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15391893 [rel_patent_id] =>[rel_patent_doc_number] =>)